Challenges in the Regulation of Autologous Stem Cell Interventions in the United States
Author:
- 1 January 2018
- journal article
- conference paper
- Published by Project MUSE in Perspectives in Biology and Medicine
- Vol. 61 (1) , 25-41
Abstract
The direct-to-consumer marketing of stem cells for unproven therapeutic uses has grown rapidly in the United States in recent years. This development is surprising since the marketing and distribution of human cell-based medical products is stringently regulated in the US. This essay describes ambiguities, gaps, and inconsistencies in the current regulatory system that have enabled such businesses to thrive. In addition to directly challenging the authority of the Food and Drug Administration (FDA) over autologous cell-based products in the courts, stem cell marketing firms have also identified and exploited regulatory loopholes, such as the same surgical procedure exception, which exempts from FDA oversight human cell-based products that are harvested and reimplanted in a single procedure. Many businesses also advertise stem cell clinical studies on a pay-to-participate basis, which requires patients to pay large sums to enroll in clinical research. This business model not only shifts many of the cost and risks of medical experimentation from providers to patients but may also indemnify sellers from fraud litigation. Lastly, stem cell advertisers borrow heavily from the language and concepts of science-based medicine in their marketing. The inaccurate promotion of autologous stem cell injections as a form of "personalized" medicine lends a veneer of credibility and precision that may encourage patients to undergo procedures of uncertain effectiveness and to sympathize with stem cell businesses in their efforts to evade oversight.Keywords
This publication has 23 references indexed in Scilit:
- Federal Regulatory Oversight of US Clinics Marketing Adipose-Derived Autologous Stem Cell Interventions: Insights From 3 New FDA Draft Guidance DocumentsMayo Clinic Proceedings, 2015
- FDA Regulation of Adult Stem Cell Therapies as Used in Sports MedicineThe Journal of Knee Surgery, 2015
- Progressive Approval: A Proposal for a New Regulatory Pathway for Regenerative MedicineStem Cells Translational Medicine, 2014
- Oversight for Clinical Uses of Autologous Adult Stem Cells: Lessons from International RegulationsCell Stem Cell, 2013
- Direct-to-Consumer Stem Cell Marketing and Regulatory ResponsesStem Cells Translational Medicine, 2013
- A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPDChest, 2013
- U.S. Regulation of Stem Cells as Medical ProductsScience, 2012
- Pay-to-Participate Funding Schemes in Human Cell and Tissue Clinical StudiesRegenerative Medicine, 2012
- The N-Of-1 Clinical Trial: The Ultimate Strategy For Individualizing Medicine?Personalized Medicine, 2011
- What Makes Clinical Research Ethical?JAMA, 2000